3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
3
Breast Neoplasms
3
Lymphoma, Non-Hodgkin
2
Leukemia
2
Triple Negative Breast Neoplasms
1
Teratoma
1
Rhabdomyosarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Glioma
1
Choriocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Embryonal
1
Burkitt Lymphoma
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
15
pembrolizumab
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
10
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Paclitaxel
7
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
pegfilgrastim
×
90 days
×
Clear all
No trials found.